<SEC-DOCUMENT>0001193125-18-279342.txt : 20180921
<SEC-HEADER>0001193125-18-279342.hdr.sgml : 20180921
<ACCEPTANCE-DATETIME>20180921070711
ACCESSION NUMBER:		0001193125-18-279342
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20180920
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Completion of Acquisition or Disposition of Assets
ITEM INFORMATION:		Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180921
DATE AS OF CHANGE:		20180921

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			XOMA Corp
		CENTRAL INDEX KEY:			0000791908
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				522154066
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-14710
		FILM NUMBER:		181080539

	BUSINESS ADDRESS:	
		STREET 1:		2200 POWELL STREET
		STREET 2:		SUITE 310
		CITY:			EMERYVILLE
		STATE:			CA
		ZIP:			94608
		BUSINESS PHONE:		510-204-7239

	MAIL ADDRESS:	
		STREET 1:		2200 POWELL STREET
		STREET 2:		SUITE 310
		CITY:			EMERYVILLE
		STATE:			CA
		ZIP:			94608

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XOMA LTD /DE/
		DATE OF NAME CHANGE:	19990107

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XOMA CORP /DE/
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d473386d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported) September&nbsp;20, 2018 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>XOMA CORPORATION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact
name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">000-14710</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">52-2154066</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>2200 Powell Street, Suite 310, Emeryville, California</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>94608</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code
<FONT STYLE="white-space:nowrap">(510)&nbsp;204-7200</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name or former address, if changed since last report.) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (<U>see</U> General Instruction A.2. below): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting material pursuant to Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (17
CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">14d-2(b)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">13e-4(c)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;
230.405 of this chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 (&#167; <FONT STYLE="white-space:nowrap">240.12b-2</FONT> of this chapter). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an
emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange
Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;1.01</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Entry into a Material Definitive Agreement. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;20, 2018, XOMA Corporation, through its wholly-owned subsidiary, XOMA (US) LLC (the &#147;Company&#148;), entered into a Royalty Purchase
Agreement (the &#147;Royalty Purchase Agreement&#148;) with Agenus Inc., and certain of its affiliates (collectively, &#147;Agenus&#148;). Pursuant to the terms of the Royalty Purchase Agreement, the Company purchased from Agenus the right to
receive <FONT STYLE="white-space:nowrap">low-</FONT> to <FONT STYLE="white-space:nowrap">mid-single</FONT> digit royalties from Incyte Europe Sarl (&#147;Incyte&#148;) (net of certain royalties payable by Agenus to a third party) and 10% of all
future developmental, regulatory and sales milestones on sales of six Incyte immuno-oncology assets, with the exception of an expected near-term milestone associated with the entry of INCAGN2390 <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">(anti-TIM-3)</FONT></FONT> into the clinic. In addition, the Company purchased from Agenus the right to receive low single digit royalties from Merck Sharp&nbsp;&amp; Dohme Corp. (&#147;Merck&#148;) and 10% of all future
developmental, regulatory and sales milestones on sales of an undisclosed Merck immuno-oncology product currently in clinical development. Pursuant to the Royalty Purchase Agreement, the Company is eligible to receive up to $59.5&nbsp;million in
potential development, regulatory and commercial milestones. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the Royalty Purchase Agreement, the Company paid Agenus $15&nbsp;million
(the &#147;Closing Amount&#148;). The Company has financed $7.5&nbsp;million of the Closing Amount by drawing a term loan under its Loan and Security Agreement with Silicon Valley Bank dated May&nbsp;7, 2018, previously filed as an exhibit to the
Company&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the three-month period ending June&nbsp;30, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Royalty
Purchase Agreement contains customary representations, warranties, covenants and indemnities. The Royalty Purchase Agreement will terminate six (6)&nbsp;months following receipt by the Company of all royalty payments to which it is entitled
thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The transaction closed on September&nbsp;20, 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing description of the Royalty Purchase Agreement does not purport to be complete and is qualified in its entirety by reference to the complete text
of the Royalty Purchase Agreement, which will be filed as an exhibit&nbsp;to the Company&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the period ending September&nbsp;30, 2018. Certain terms of the Royalty
Purchase Agreement have been omitted from this <FONT STYLE="white-space:nowrap">Form&nbsp;8-K&nbsp;and</FONT> will be omitted from the version to be filed as an exhibit to the <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q&nbsp;pursuant</FONT> to a
Confidential Treatment Request that the Company plans to submit to the Securities and Exchange Commission at the time of the filing of the <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q.</FONT> On September&nbsp;21, 2018, the Company issued a press
release attached hereto as Exhibit 99.1 </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;2.01</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Completion or Acquisition or Disposition of Assets. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information included under Item 1.01 of this Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> is incorporated by reference herein. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;2.03.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Creation of a Direct Financial Obligation or an Obligation under
<FONT STYLE="white-space:nowrap">an&nbsp;Off-Balance&nbsp;Sheet</FONT> Arrangement of a Registrant. </B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information included under
Item 1.01 of this Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> is incorporated by reference herein. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Financial Statements and Exhibits. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="d473386dex991.htm">Press Release dated September&nbsp;21, 2018 </A></P></TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">XOMA CORPORATION</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: September&nbsp;21, 2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Thomas Burns</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Thomas Burns</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Senior Vice President, Finance and Chief Financial Officer</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d473386dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g473386g07t87.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>XOMA Acquires Royalty Interest Position from Agenus on Seven Assets Being Developed by Merck and Incyte
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>EMERYVILLE, Calif., September</B><B></B><B>&nbsp;21, 2018 (GLOBE NEWSWIRE)</B> &#150; XOMA Corporation (NASDAQ: XOMA), announced today that for
$15.0&nbsp;million, it has acquired from Agenus (NASDAQ: AGEN) a partial interest position in the rights to potential milestone and royalty payments associated with seven immuno-oncology antibodies currently being developed by Merck and Incyte under
their collaborations with Agenus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;This is an important deal reflecting our new royalty-aggregator strategy to acquire milestone and royalty
payments associated with therapeutic candidates partnered by others. The basket of Agenus immuno-oncology assets is advancing in the hands of two of the leading companies in oncology drug development,&#148; said Jim Neal, Chief Executive Officer at
XOMA. &#147;These assets possess all the characteristics we have established for our business model: outstanding development partners, <FONT STYLE="white-space:nowrap">mid-stage</FONT> to early stage assets, important therapeutic categories, and
sizable royalty commitments. We believe this investment could generate potential future cash flows over an extended period from milestones and royalties on some exciting potential commercial opportunities.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The seven royalty interest antibodies are: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">One Phase 1 antibody being developed by Merck on an undisclosed novel target; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Incyte&#146;s INCAGN1876, a GITR agonist in Phase 1/2 studies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Incyte&#146;s INCAGN1949, an <FONT STYLE="white-space:nowrap">OX-40</FONT> agonist in Phase 1/2 studies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Incyte&#146;s INCAGN2385, a <FONT STYLE="white-space:nowrap">LAG-3</FONT> antagonist in Phase 1 studies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Incyte&#146;s INCAGN02390, a <FONT STYLE="white-space:nowrap">TIM-3</FONT> antagonist expected to enter the
clinic in 2018; and, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Two preclinical antibodies being developed by Incyte on undisclosed targets. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the agreement, XOMA will receive <FONT STYLE="white-space:nowrap">low-</FONT> to <FONT STYLE="white-space:nowrap">mid-single-digit</FONT>
royalties on future sales of these seven immuno-oncology assets. Additionally, XOMA is entitled to a portion of milestone payments associated with the assets. XOMA has drawn $7.5&nbsp;million from its line of credit with Silicon Valley Bank
(&#147;SVB&#148;) to partially fund this transaction. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About XOMA Corporation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">XOMA has built a significant portfolio of products that are licensed to and being developed by other biotechnology and pharmaceutical companies. The
Company&#146;s portfolio of partner-funded programs spans multiple stages of the drug development process and across various therapeutic areas. Many of these licenses are the result of XOMA&#146;s pioneering efforts in the discovery and development
of antibody therapeutics. The Company&#146;s royalty-aggregator business model includes acquiring additional licenses to partner-funded programs. For more information, visit www.xoma.com. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain statements contained in this press release are forward-looking statements within the meaning of Section&nbsp;27A of the Securities Act of 1933 and
Section&nbsp;21E of the Securities Exchange Act of 1934, including statements regarding the potential of XOMA&#146;s portfolio of partnered programs and licensed technologies to generate royalty proceeds over time and create potential cash flow,
including from potential milestone and royalty payments associated with immuno-oncology programs of Agenus. These statements are based on assumptions that may not prove accurate, and actual results could differ materially from those anticipated due
to certain risks inherent in the biotechnology industry, including those related to the fact that we may not receive any significant royalty or milestone payments from Agenus&#146; assets, our product candidates subject to <FONT
STYLE="white-space:nowrap">out-license</FONT> agreements are still being developed, and our licensees may require substantial funds to continue development which may not be available; we do not know whether there will be, or will continue to be, a
viable market for the products in which we have an ownership or royalty interest; we may not be successful in entering into <FONT STYLE="white-space:nowrap">out-license</FONT> agreements for our product candidates; if our therapeutic product
candidates do not receive regulatory approval, our third-party licensees will not be able to manufacture and market them. Other potential risks to XOMA meeting these expectations are described in more detail in XOMA&#146;s most recent annual report
on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> in subsequent quarterly reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> and in other SEC filings. Consider such risks carefully when considering XOMA&#146;s prospects. Any
forward-looking statement in this press release represents XOMA&#146;s views only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date. XOMA disclaims any obligation to update any
forward-looking statement, except as required by applicable law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor contact: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Juliane Snowden </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Oratorium Group, LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">646-438-9754</FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">jsnowden@oratoriumgroup.com </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media contact: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kathy Vincent </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">KV Consulting&nbsp;&amp; Management </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">310-403-8951</FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">kathy@kathyvincent.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">### </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g473386g07t87.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g473386g07t87.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M+>1PL!>:C.?)L-/![RRD8!QR%&7/937UQ_P3]_X(C:W\9TL?%GQ86]\,^%I
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ME4?B6.2222:RO@-^S_XJ_:9^)EAX3\'Z9)J6K7QR?X8;6,$;II7Z)&N>2?4
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MS0VFLVDDP^BF0;C[+FOF/Q_\/M=^%WBFYT/Q)H^I:%K%DVV>SOK=H)H_3*L
M<'J#T(Y%=F'X9X8QD7##1C*W\LVVOND<&(XNXPP$E/&2G!/^:FDG]\5^!_0-
M^R9_P4E^$O[9<HLO"?B!K?7]AD;1-4C^RWX4#)*KDK( .IC9L=\5[Q7\M_A_
MQ'J'A#7;/5=*O;K3=2T^9;BUNK:0QS6\BG*NK#D,",@BOZ"/^"7W[8DO[:O[
M)^D^)-2:+_A)M)F;1]<$8"J]S$JGS0!T$D;H^   S,!P*_/N,.#5E<5BL*VZ
M;=FGO%]->J?X>=S]0X$X\EG$G@\9%1JI736TDM].C7X^5CZ(KX7_ &E_^"\?
MP]_9L^.GB3P+<^$O%6MW7AFZ^Q7%Y9R6ZPR2A5+JH9P?E8E3D=5-?:?CKQA9
M_#WP3K&OZ@_EZ?H=C/J%RW]V**-I'/\ WRIK^7SXE^.+SXF_$'7?$FHMNU#Q
M!J-QJ5R<YS)-(TC?JQJ.!^'</F=2K/%IN$4DK-K5^G9+\33Q#XJQ644Z,,$T
MIS;;ND]%Z]V_P/UT/_!RO\-A_P T\\<?]_K7_P"+KZ*_X)]?\%/O"_\ P4+U
M3Q19^'_#NO:#-X6BMIIO[1>)A.LQD V[&/0Q\Y_O"OYXG^]7Z5_\&T6L>3\?
M_B5I^?\ CY\/P7&/7R[@+_[5_6OI>).#<MPF6U<3AXM2BDUJWU5_P/D^$^.\
MVQV:T<+BIIPDVFN5+HVM5YV/V,HHHK\>/W0CNKJ.QM9)II(X885+R2.P544#
M)))X  YR:_.7QK_P<L?"CPUXOU/3K#P9XSUJSL;J2WAU"![:.*]1&*B5 S[@
MK8W#< <$9 /%7O\ @X"_;V_X41\#X_A3X<O?+\5_$"W8ZD\3XDL-*R5?/HT[
M!HQ_L++T.TU^'+]:_2N$>#Z&,PSQ6.3M+X5=K1;OY[+T\S\GXUXXQ&"Q:P>7
MR5X_$[)ZO9:]EJ_6W1G[1'_@YX^&8_YISXZ_[_6O_P 77V%^P'^W)I?[?_P>
MOO&FB^&]:\.Z7::G)I<:ZD\3/<ND<;LZ^6Q&T>8%Y[@^E?S*GI7]+'_!*KX'
M_P##/G_!/[X8Z!)#Y-]/I":M>@CYO/NR;E@WNOFA/^ "IXPX?RW+<+&6'BU.
M4K+5O2UW^GWFG _$F:YIC)0Q,TX1C=VBEJVDMOF_D?0E%%%?FY^J'#_M(?M#
M>&?V5?@IX@\>^+KS['H?A^V,\NW!EN')VQPQ@D;I)'*HHR!EAD@9(_/4_P#!
MTG\+P/\ DFOCW_O]:?\ QROD?_@O!_P4I_X:[^-W_"O_  GJ'F_#KP'=.GFP
MOF+6M17*27&1PT<>6CC/((+L"0XQ^?C_ ':_5,AX)P\\*JN/3YY:VNU9=-NO
M5]MC\=XCX^Q,,8Z.727)'2]D[OJU?IT7??L?T8_\$]_^"U'@;_@H9\:-0\#Z
M%X6\2^'=3LM)DU=9=2>!HITCEBC9%\MB=W[T-TQA6_'[,K^<+_@@Q\1_^%=_
M\%0_A\KMLM_$"7NCR\XSYMK*8Q_W]2.OZ/:^3XLRFCE^-5+#JT7%/>_5I_D?
M;<&YS7S+ NMB'>:DUM;HFOS"BBBOESZPYGXR_#F#XM_"_6O#MQMQJ5LR1,W2
M.4?-&_\ P%PI_"ORPU/39]&U*XL[J-H;FUE:&6-A\R.I(8'Z$$5^NM?'_P"U
MI\+O ?[/?Q"USXN>.[N!O"JJEQ;:+'S<:QJ9!_<*IX96*[SSCYF+856S^<\<
M<%XO/*^&_LZ/-5<N1^CU3](N_P!Y\QQ)A8NFL3)J*C\3>B4=[OT_4X'X-_$V
MW_8&^"VL?%+QE</!;^(;86F@^'U(6ZUV8'<D@S]Q%R?G(("N3SE _P":O[2'
M[1WBC]J?XJW_ (N\67IN;Z[.R&%,B"PA!.R&)2?E1<GW)))))).I^UA^U1XF
M_:[^+%SXH\1S"-<>3I^GQ,?L^EVX/RQ1C]2V,L<D]@.6^#?P=\0_'SXDZ7X3
M\+Z?)J6M:O+Y4,2\*@ZM([=%15!9F/  )K^OO#7P[P?"&41IU)<U1)N4GLKZ
MM+HE?5G\T<5\55LYK0R_ W]A%VC'K.3?Q-=W]E=%YME[]G3]G+Q1^U/\5=/\
M(^$[$W6H7AW2S/D06,((WSS-@[47/7J20 "Q /[E_L6?L3^$_P!B;X8)H>@1
M"\U6\"R:MK$L8%QJ4H'?^[&N3MC!PH/=BS&M^PM^Q%X=_8C^$L>BZ:([_7]0
M"S:UJY3$E],!]U>ZQ)DA$[#).69B?;:^%XTXRGFE1X;#.U"+_P# GW?EV7S>
MNW[CX?\  -/)J*Q>+2EB)+U4$^B\^[^2TW^5?^"MG[;,W[(/[.WV?0[KR/&G
MC)I+#274_/91@#S[H>Z*RJOH\B'D*17X774[W,K22,TDDC%F9CEF)ZDGUKZE
M_P""OW[0S_'W]MCQ%'!/YNC^#C_PC]@H;*YA)\]O3+3F3GNJKZ5X9^SM\&;W
M]H?XZ>%/!-@62X\2:E%9M(HSY$1.99<>B1AW/LM?J'!^4TLJRA5JNDI+GF^R
MM=+Y+\;GX[QYG5;.L\="CK"$N2"[N]F_64NO:W8^V?\ @CM_P2XT_P"-MI#\
M5/B-IXO/#,4Q70M(G7]UJLB-AKB8?Q0JP*JG1V5L_*N'_6RTM(=/M(K>WBCA
M@A01QQQJ%2-0,!0!P !Q@5G^"/!FF_#GP;I7A_1[6.RTG1;2*RLX$'RQ11J$
M5?P '-:E?A_$.?5\UQ<J]5^[]F/1+_/N^K/Z+X7X;P^2X*.&HI<UES2ZREU^
M2Z+HO.X5\)_\%\_V=='^(/[(C^/?LD,?B+P+=VYCNU0"26TGF6%X&/=0\B.,
M]"IQC<V?NROD7_@N/XKC\-_\$Z/%EN[*LFM7VGV,(/\ $WVJ.8@?\ A8_A1P
MQ4J0S;#ND[/GBODW9_A<.,*5*IDF*5977))_-*Z_&Q^#;]*_5O\ X-IM6N)?
M#?Q>L69C:PW6ESHO97=;I6/XA%_(5^4C]*_8#_@V[\#R:9^S_P#$+Q$Z,L>L
M:_#8QDC[XMX QQ^-P17[1Q].*R2JGU<;?^!)_DF?@/AE3E+B"BX]%)OTY6OS
M:/:_^"V?QH_X4[_P3W\6QPR^5?>+I(/#UMS]X3-NF'XP1S#\:_ &7^M?J/\
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MFG]L87G]M=MMR;O?>Z?<]_%\75<12J4Y48KG33?O7U]9-?@1/UK^E;_@B/\
M$?\ X69_P3 ^%-TTF^;2[";2)0?X/LMS+"@_[]HA^AK^:E^M?NW_ ,&P7Q'_
M .$D_8B\5>'9'W3>&?%<S(N?NPW%O"Z_^1%EKV./J'/ERG_+)/[[K]4>KX<X
MCDS1TW]J+7S33_),_1GQ-XFT_P &>'KW5M6O+?3],TV%KBZN9W"1P1J,LS$]
M  *_&/\ X*4?\%$-0_;%\:'1]%DN+#X>Z-,38VS91]2D&1]IF'KC.Q3]T'^\
M37T?_P %.-4^._[5.KOX1\'_  Y\96GP_P!/E#2.;7RY-<F4\2.,Y$2GE$/4
M_,W.T+\<R?\ !.?XY'_FF/BGI_S[C_&M^ \CR[!1688^M#VK^&+E'W%W>OQ/
M\%Y[>5XF<29KF,WE664*GL4_>DH2]]KHM/A7_DSUVM?Q2TL9M3NX;:VAEN+B
MX=8HHHD+O*[' 50.222  .M?KU_P2Q_X)GP_LS:)!XZ\:6D4WQ U*'_1[9P&
M70(6'*#MY[ X=A]T$H.-Q;%_X)8_\$O3\#$M_B%\1-/C;QE(-VEZ9+AUT1#Q
MYKXR#.PZ?\\P?[Q.W[LKSN/N./K+EEN7R]S:4E]KR7]WN^OIOZWAGX<_5%'-
M\TC^\WA!_9_O27\W9?9W?O;?"_\ P7C^!/\ PG7[->D>-K6'=>^"-0"7#!>?
MLER5C;/TE$'T#-7Y!U_1Y\;?A=9_&WX0>)O"-_M^R^(M-GL&8C/E%T(5Q[JV
M&'NHK\-KW_@FC\=[&\FA/PQ\32&%RA>.%71L'&5(."#V/>O8\-\_H++Y8/$U
M%%TY:7:6DM=+]G?[T>%XM\,XF6:0Q^$I2FJD?>Y8MVE'36RTO&UO1GZ#_P#!
M"']H_P#X6-^SKJ7@&^GWZGX$N=UJ&;YGL;@LZ8[G9*)1[!HQZ5]9_M*_"H_'
M']GWQIX01E2;Q%HUU8P,QPJ2O&PC8^P?:?PK\N?^":7[.WQT_94_:W\.ZY??
M#?Q9;^'M4+:1K+&W 5+:8@>8W/2.01R'OA#ZU^OM?!\:4:6%SAXK!3C)2:FN
M5IVE?7;S5_F?I?A_B*^-R%8/,*<HR@G3:DFKQMHU=?RNWR/YD]=T:Z\.:Q=:
M??6\MI?6,SV]Q!*NUX9$8JR,.Q!!!'M79?LN_M+^(OV2/C1I7C;PR\1OM/+1
MS6TV3#?0/Q)#(!SM8=QR&"L.0*_4S_@I%_P1SMOVG/$]YXZ^']Y8Z'XQO/GU
M&QNLI9:LX'^L#*"8ICC!."KG!.T[F/YK?%W_ ()Y_&KX))/)X@^'?B*.UMR=
M]W:0B^M@/7S(2Z@'W(K]AROB;*\WPO).44Y*TH2:3UW6NZ[-?@S\)SCA'.<B
MQGM*<).,'>-2*;6CNFVOA?=/\5J?IG\+/^"^_P &O%NDPMXFL_$WA#4-O[Z.
M2S^W6ZM_L21$LP]S&I]J;\4/^"_WP8\(:7(WAVQ\5>+;['[J..S%E 3_ +4D
MI#*/<(WTK\9;FWDBG:%HW653M*%<,#GICUKM/A]^RQ\2OBU,L?AOP)XKUDMS
MNMM,E9 /4MMV@>Y->)6\/<BI2]M4<HQ[.22^]J_XGT.'\4.(ZT/84E&4NZ@W
M+[D[?^2G??MT_P#!2/Q]^W5K$,>N20Z+X7L9?-LM!L7;[/$^"!)*QYFDP2-S
M8 R=JKDY\5^&WPRU[XQ^.],\,^&-+NM9US5YA!:VENFYY&/<]E4#)+' 4 DD
M $U]A? #_@@W\9OBI?6\OBM-+^'VD,0TDE[.MW>%?]B"%B,^SNE?J'^Q=_P3
MV^'G[#OAR2'PO8R7NO7D82_UV^VR7MT."4! Q''D9V( . 3N(S4YEQ=E&48;
MZMEUI26T8_"O-R_.S;?7N:93P/GF>8OZWFO-"+?O2GI)KM&+U7E=)+I?8S?^
M";O[!^E_L(? F/1]T%]XLUHI=^(-1C'RSS ';#&3SY40)5<]27; +8'D7_!?
MWXT?\*X_8;;P[#+LO/'6K6^GE0<-]GB)N)#]-T<2G_KI7W%7Y?\ _!=GX ?%
M[]I[XS>#],\%^!/$GB'PWX9TF24W5I"&A:[N)/WBCGJJ0P_]]&OS/AVM]=SR
M&*QTUOSMMI*ZU6_G9)=C]<XIH?V=P[4P>74W\*A%13;LW9[:[7;?5GY*R5_0
MW_P23^$/_"F/^"?/PXT^2+RKO5M/.MW.1AF:[=IUS[B-XU_X#7XX^$/^"47Q
M\\1^+M*T^Z^&/BG3[6^O(K>:ZFMU6.V1G"M(Q)X5022?:OZ$?#^AVOAC0;'3
M;*,0V>GV\=M!&.B1HH51^  %?6^(^;4:N'HX:A-2NW)V:>RLKV]7]Q\3X4Y+
MB*.)KXO$TW&T5%<R:O=W=K]K+[S\R_\ @YGT3S_AM\)]2V_\>NIZA;$_]=(H
M6_\ :5?D+YS0/N1F1AT*G!%?NQ_P7C_9K\9?M)_LT>$[/P/X<U'Q-J^E^)4G
MEMK) \D<#6MPK/@D?*&\L?5A7Y1R?\$L?VB#_P TC\8?^ H_QKU^!\RPT,HA
M3JU(Q:<M&TGNWU?F>+X@Y3BZF=U*M&E*2DHZJ+:^%+=+R/'OA%\)=<^._P 4
MM"\'>&[1KW7/$=Y'8VD71=S'[S'^%%&69NBJI)X%?TK_ +(_[,^A_LA?L^>&
M_ .@JK6VB6P%Q<[-KW]RWS33O[NY)QD[1M4<**^(O^"%O_!,?7/V=KK6OB=\
M2-!GT?Q;<!M,T/3[M1YUA;\>=<$9.UY#\B]"$5^TE?I'*_E1LV&;:"<*,D_2
MOC>/.(%C,0L'AY7IPW:V<O\ );>MS[SPYX9E@<,\=B8VJ5-D]XQ_1MZORMYG
MX6_\'%OQV_X63^VW9^$K>;S++X?Z-%:N@.0MU<XN)3_W[:W4^Z5\X_\ !-/X
M(?\ #0_[=_PR\,20^?9RZS%?7J8RK6UKFYE!]F2(K_P*O2?VDOV"?VE/V@_C
M[XR\;W7P@\;"7Q1J]SJ(1[4;H4DD8I'][^!-JCV6OK;_ (((_P#!._X@_ C]
MHCQ5XY^(W@W5O"XTW11IVDKJ$81IY9Y 9'09)^2.(J3_ --J^SJ8_"Y=D?LJ
M52+G&%K*2;YFNR?=W/A:66XS-.(?;5J4E"=2[;BTN5.]KM?RJQ]W_P#!0[]M
MS1?V"_V;-6\9:AY-UK$N;+0=-=L'4;UE.Q3CGRUP7<CHJD#YBH/\U?Q-^(NM
M?%SQ]K'BCQ%?S:IKFO74E[?74IRTTKL68^@'. !P     !7Z#?\ !4[X/_M.
M_M_?M(76L0?"'QY;^"] WV'AJQDM IC@S\T[KNP)9B S>BA%R=@)X']A[_@B
M3\6/B[^TCH.G_$GP/KWA'P):2?;=9N[U1";B",@_9XB#GS)3A,C[JEF_AP>#
MAFE@,IP+KUZL?:25Y6:;2Z16N_?N_D>EQ96S'.LPCA\/2G[.+M&\6DV]Y/31
M=K[+U9]1?\$"?^"7.BS?"ZX^,'Q+\-:9K4OBB(V_AK3=6LTN88++/SW9CD!7
M?*PPA(R(U+ D2\?HO_PQU\(C_P TK^''_A-67_QNN^T;1[7P[I%KI]A;0V=C
M8PI;V]O"@2."-%"JBJ. H4  #@ 59K\SS3.L3C<5+$2DU?9)O1=%_774_6<H
MR'"X#"0PT8IV6K:5V^K_ *V6AYO_ ,,<_"'_ *)7\-__  F;+_XW7E/[=7[$
M?PQUC]B_XK0Z/\-_ >FZLOA34IK&ZM/#]I#/!/';221LCK&&5@RC!!S7T]6?
MXKT"+Q7X7U+2Y\&'4K66UD!_NNA4_H:XZ&.K0JQGSO1I[OHSMQ&7T*E*5/D6
MJ:V75'\AK]:_6+_@U5^(;6GQ'^+WA1I/EU#3=/U:-#V,$LL3D?7[0GY"OBR_
M_P""1'[2EM>RQ+\'?&<@C<H'6U4JV#C((;&#7I/[)?[(G[7O[&_Q"O\ Q'X5
M^#GC5;S4-.;390;;:#&TD<G8^L8K]JSVIA<;@:F&A6A>25O>6Z:?<_!^'Z.,
2P&84\5.C.T6[^Z]FFNWF?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
